Skip to main content

Table 3 Summary of clinical courses

From: Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis

Case Treatment Response to treatment Overall survival duration (months) Relapse Outcome Cause of death
 1 R-CHOP ×5 PR 45.0 No Dead Cholangiocarcinoma
(75% dose)
 2 R-CHOP ×6 PR 7.9 No Dead Pneumonia
IT*
 3 R-CHOP ×2 NA 4.0 Dead Exacerbation of pulmonary fibrosis
(70% dose)
 4 R-MPV ×4 CR 40.1 No Alive
IT*
HD-Ara-C ×2
WBRT
 5 R-CHOP ×6 CR 28.0 No Alive
HD-MTX ×2
IT*
 6 R-CHOP ×8 CR 24.8 No Alive
IT*
 7 R-COP ×1 NA 2.6 Dead Pneumonia
(60% dose)
  1. *IT represents prophylactic administration of methotrexate and/or cytarabine.
  2. CR complete response, CRu unconfirmed complete response, HD-Ara-C high-dose cytarabine, HD-MTX high-dose methotrexate, IT intrathecal themotherapy, NA not assessable, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, R-COP rituximab, cyclophosphamide, vincristine, and prednisolone, R-MPV rituximab, high-dose methotrexate, procarbazine, and vincristine, WBRT Whole-brain radiotherapy.